成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

HUMAN LEUKOCYTE IFN

HUMAN LEUKOCYTE IFN Struktur
284690-33-1
CAS-Nr.
284690-33-1
Englisch Name:
HUMAN LEUKOCYTE IFN
Synonyma:
IFL;IFN;IFNA13;α-IFN-Le;INTERFERON;HUMAN LEUKOCYTE IFN;Interferon-γ human;Interferon-γ porcine;Interferon β from rat;HUMAN LEUKOCYTE INTERFERON
CBNumber:
CB0281625
Summenformel:
Molgewicht:
0
MOL-Datei:
Mol file

HUMAN LEUKOCYTE IFN Eigenschaften

storage temp. 
−20°C
Aggregatzustand
buffered aqueous solution
CAS Datenbank
284690-33-1

Sicherheit

Kennzeichnung gef?hrlicher B
S-S?tze: 23-24/25

HUMAN LEUKOCYTE IFN Chemische Eigenschaften,Einsatz,Produktion Methoden

S-S?tze Betriebsanweisung:

S23:Gas/Rauch/Dampf/Aerosol nicht einatmen(geeignete Bezeichnung(en) vom Hersteller anzugeben).
S24/25:Berührung mit den Augen und der Haut vermeiden.

Pharmazeutische Anwendungen

A human protein produced by recombinant DNA technology in Escherichia coli, formulated for administration by intramuscular, subcutaneous or intralesional injection. A pegylated form, peginterferon, developed by attaching a 40 kDa branched-chain polyethylene glycol moiety to interferon- α-2a, has a prolonged half-life and is better tolerated. Potency is expressed as international units (IU), defined as the amount needed to prevent lysis of 50% of cells by vesicular stomatitis virus in tissue culture assay.

Mechanism of action

Although interferons are mediators of immune response, different mechanisms for the antiviral action of interferon have been proposed. Interferon-α possesses broad-spectrum antiviral activity and acts on virus-infected cells by binding to specific cell surface receptors. It inhibits the transcription and translation of mRNA into viral nucleic acid and protein. Studies in cell-free systems have shown that the addition of adenosine triphosphate and double-stranded RNA to extracts of interferon-treated cells activates cellular RNA proteins and a cellular endonuclease. This activation causes the formation of translation inhibitory protein, which terminates production of viral enzyme, nucleic acid, and structural proteins. Interferon also may act by blocking synthesis of a cleaving enzyme required for viral release.

Pharmakokinetik

Oral absorption: Poor
Cmax 3 × 106 IU intramuscularly: 20 IU/mL after 2–4 h
9 × 106 IU intramuscularly: 50–100 IU/mL after 2–4h
Plasma half-life: 3–8 h
Peginterferon: 36 h
Plasma protein binding: Not known
Cerebrospinal fluid (CSF) penetration is poor. It is not cleared by hemodialysis. Little or none is excreted in the urine, and its fate after release from the cell receptor is largely unknown. The extent of excretion in breast milk is unknown.

Clinical Use

Chronic hepatitis B
Chronic hepatitis C (in combination with ribavirin)
Condyloma acuminata (intralesional)
It may also be of benefit in hairy cell and chronic myelogenous leukemias and Kaposi’s sarcoma.

Nebenwirkungen

Toxicity has become increasingly apparent with the advent of purer preparations. ‘Flu’-like symptoms (fever, arthralgia, myalgia, headache, malaise, chills) occur, which can usually be ameliorated by acetaminophen (paracetamol) administration. Lymphocytopenia is common, generally arising 2–4 h after administration of several million units. Liver function test values are frequently elevated at doses above 107 IU/day. These effects are rapidly reversible and tolerance may develop after several doses. Other toxic effects include gastrointestinal disturbances (anorexia, nausea, diarrhea, vomiting), weight loss, local pain, severe fatigue, alopecia, paresthesias, confusion, dizziness, drowsiness, nervousness and bone marrow suppression. Neutropenia and thrombocytopenia are dose dependent (threshold around 3 × 106 IU/day) and reversible. Hypotension may develop during, or up to 2 days after, treatment, and arrhythmias and cardiac failure have been observed.
Administration of excessive doses to pregnant rhesus monkeys in the early to mid-trimester caused abortions. Its effect on human pregnancy is unknown. Neutralizing antibodies have been reported in about 25% of treated patients but no clinical sequelae to their presence have been documented. Intralesional administration in the treatment of condylomata acuminata is generally well tolerated.
Peginterferon is also associated with fatigue, headache, myalgia and fever; most other side effects occur less frequently.

HUMAN LEUKOCYTE IFN Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


HUMAN LEUKOCYTE IFN Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Global( 20)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Career Henan Chemica Co
+86-0371-86658258 +8613203830695
laboratory@coreychem.com China 30240 58
Sigma-Aldrich 021-61415566 800-8193336
orderCN@merckgroup.com China 51456 80
Shanghai Yaji Biological Technology Co., Ltd. 021-34661275 15301693058
yajikit@163.com China 9670 58
ACROBiosystems 18514007688
jiaxin.zhao@acrobiosystems.com China 1145 58
Olix (Shanghai) Pharmaceutical Technology Co., Ltd 17316404525
209533805@qq.com China 9762 58

284690-33-1()Verwandte Suche:


  • ANTI-IFNA1 antibody produced in mouse
  • IFL
  • IFNA13
  • INTERFERON
  • IFN
  • HUMAN LEUKOCYTE IFN
  • HUMAN LEUKOCYTE INTERFERON
  • α-IFN-Le
  • Interferon β from rat
  • Interferon-γ porcine
  • Interferon-γ human
  • Interferon β from mouse
  • Interferon from human leukocytes
  • 284690-33-1
Copyright 2019 ? ChemicalBook. All rights reserved